_id

690f351fccc777a4e85d16c2

Ticker

BHVN

Name

Biohaven Pharmaceutical Holding Co Ltd

Exchange

NYSE

Address

215 Church Street, New Haven, CT, United States, 06510

Country

USA

Sector

Healthcare

Industry

Biotechnology

Currency

USD

Website

https://www.biohaven.com

Description

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Last Close

11.44

Volume

2765604

Current Price

11.53

Change

0.7867132867132856

Last Updated

2025-11-28T12:53:00.269Z

Image

data:image/webp;base64,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

Ipo Date

2022-09-23T00:00:00.000Z

Market Cap

1257886848

Next Dividend Date

-

Dividend Frequency

-

Dividend Rate

-

Dividend Yield

0

Sentiment

0.7817999999999999

Sentiment Sources

21

Rating

4.625

Target Price

20.75

Strong Buy

11

Buy

4

Hold

1

Sell

0

Strong Sell

0

Current Quarter

2025-09-30

Revenue

0

Cost Of Revenue

1105000

Gross Profit

-1105000

Operating Expenses

168277000

Operating Income

-169382000

Interest Expense

-

Pretax Income

-173222000

Net Income

-173443000

Eps

-1.6391148486853069

Dividends Per Share

-

Shares Outstanding

132688489

Income Tax Expense

221000

EBITDA

-172117000

Operating Margin

-

Total Other Income Expense Net

-3840000

Cash

184847000

Short Term Investments

75370000

Receivables

-

Inventories

-

Total Current Assets

323615000

Property Plant Equipment

62722000

Total Assets

409123000

Payables

17491000

Short Term Debt

5512000

Long Term Debt

268270000

Total Liabilities

426283000

Equity

-17160000

Depreciation

3125000

Change In Working Capital

-3011000

Cash From Operations

-145716000

Capital Expenditures

13000

Cash From Investing

164967000

Cash From Financing

122000

Net Change In Cash

19387000

PE

-

PB

-71.09833264219114

ROE

1010.7400932400932

ROA

-42.393852215592865

FCF

-145729000

Fcf Percent

-

Piotroski FScore

1

Health Score

39

Deep Value Investing Score

1

Defensive Investing Score

7

Dividend Investing Score

1.5

Economic Moat Investing Score

5.3

Garp Investing Score

2

Growth Investing Score

2

Momentum Investing Score

3

Net Net Investing Score

0.5

Quality Investing Score

2.5

Value Investing Score

2.5

Quarters > 0 > quarter

2025-09-30

Quarters > 0 > income Statement > revenue

0

Quarters > 0 > income Statement > cost Of Revenue

1105000

Quarters > 0 > income Statement > gross Profit

-1105000

Quarters > 0 > income Statement > operating Expenses

168277000

Quarters > 0 > income Statement > operating Income

-169382000

Quarters > 0 > income Statement > interest Expense

-

Quarters > 0 > income Statement > pretax Income

-173222000

Quarters > 0 > income Statement > net Income

-173443000

Quarters > 0 > income Statement > eps

-1.6391148486853069

Quarters > 0 > income Statement > dividends Per Share

-

Quarters > 0 > income Statement > shares Outstanding

105815038

Quarters > 0 > income Statement > income Tax Expense

221000

Quarters > 0 > income Statement > EBITDA

-172117000

Quarters > 0 > income Statement > operating Margin

-

Quarters > 0 > income Statement > total Other Income Expense Net

-3840000

Quarters > 0 > balance Sheet > cash

184847000

Quarters > 0 > balance Sheet > short Term Investments

75370000

Quarters > 0 > balance Sheet > receivables

-

Quarters > 0 > balance Sheet > inventories

-

Quarters > 0 > balance Sheet > total Current Assets

323615000

Quarters > 0 > balance Sheet > property Plant Equipment

62722000

Quarters > 0 > balance Sheet > total Assets

409123000

Quarters > 0 > balance Sheet > payables

17491000

Quarters > 0 > balance Sheet > short Term Debt

5512000

Quarters > 0 > balance Sheet > long Term Debt

268270000

Quarters > 0 > balance Sheet > total Liabilities

426283000

Quarters > 0 > balance Sheet > equity

-17160000

Quarters > 0 > cash Flow > net Income

-173443000

Quarters > 0 > cash Flow > depreciation

3125000

Quarters > 0 > cash Flow > change In Working Capital

-3011000

Quarters > 0 > cash Flow > cash From Operations

-145716000

Quarters > 0 > cash Flow > capital Expenditures

13000

Quarters > 0 > cash Flow > cash From Investing

164967000

Quarters > 0 > cash Flow > cash From Financing

122000

Quarters > 0 > cash Flow > net Change In Cash

19387000

Quarters > 0 > ratios > PE

-1.6391148486853069

Quarters > 0 > ratios > PB

-71.09833264219114

Quarters > 0 > ratios > ROE

1010.7400932400932

Quarters > 0 > ratios > ROA

-42.393852215592865

Quarters > 0 > ratios > FCF

-145729000

Quarters > 0 > ratios > Piotroski FScore

1

Quarters > 0 > ratios > fcf Percent

-

Quarters > 0 > health Score

39

Quarters > 1 > quarter

2025-06-30

Quarters > 1 > income Statement > revenue

0

Quarters > 1 > income Statement > cost Of Revenue

-

Quarters > 1 > income Statement > gross Profit

-

Quarters > 1 > income Statement > operating Expenses

211701000

Quarters > 1 > income Statement > operating Income

-211701000

Quarters > 1 > income Statement > interest Expense

-

Quarters > 1 > income Statement > pretax Income

-197886000

Quarters > 1 > income Statement > net Income

-198147000

Quarters > 1 > income Statement > eps

-1.9355430474612305

Quarters > 1 > income Statement > dividends Per Share

-

Quarters > 1 > income Statement > shares Outstanding

102372820

Quarters > 1 > income Statement > income Tax Expense

261000

Quarters > 1 > income Statement > EBITDA

-209723000

Quarters > 1 > income Statement > operating Margin

-

Quarters > 1 > income Statement > total Other Income Expense Net

13815000

Quarters > 1 > balance Sheet > cash

165797000

Quarters > 1 > balance Sheet > short Term Investments

239183000

Quarters > 1 > balance Sheet > receivables

-

Quarters > 1 > balance Sheet > inventories

-

Quarters > 1 > balance Sheet > total Current Assets

474827000

Quarters > 1 > balance Sheet > property Plant Equipment

52835000

Quarters > 1 > balance Sheet > total Assets

550415000

Quarters > 1 > balance Sheet > payables

19628000

Quarters > 1 > balance Sheet > short Term Debt

4696000

Quarters > 1 > balance Sheet > long Term Debt

257070000

Quarters > 1 > balance Sheet > total Liabilities

415828000

Quarters > 1 > balance Sheet > equity

134587000

Quarters > 1 > cash Flow > net Income

-198147000

Quarters > 1 > cash Flow > depreciation

1978000

Quarters > 1 > cash Flow > change In Working Capital

18558000

Quarters > 1 > cash Flow > cash From Operations

-167936000

Quarters > 1 > cash Flow > capital Expenditures

233000

Quarters > 1 > cash Flow > cash From Investing

-15546000

Quarters > 1 > cash Flow > cash From Financing

249830000

Quarters > 1 > cash Flow > net Change In Cash

66308000

Quarters > 1 > ratios > PE

-1.9355430474612305

Quarters > 1 > ratios > PB

8.770227545008062

Quarters > 1 > ratios > ROE

-147.22595793055794

Quarters > 1 > ratios > ROA

-35.999563965371586

Quarters > 1 > ratios > FCF

-168169000

Quarters > 1 > ratios > Piotroski FScore

1

Quarters > 1 > ratios > fcf Percent

-

Quarters > 1 > health Score

17

Quarters > 2 > quarter

2025-03-31

Quarters > 2 > income Statement > revenue

0

Quarters > 2 > income Statement > cost Of Revenue

1014999

Quarters > 2 > income Statement > gross Profit

-1014999

Quarters > 2 > income Statement > operating Expenses

221561000

Quarters > 2 > income Statement > operating Income

-221561000

Quarters > 2 > income Statement > interest Expense

-

Quarters > 2 > income Statement > pretax Income

-221068000

Quarters > 2 > income Statement > net Income

-221677000

Quarters > 2 > income Statement > eps

-2.1745190940035117

Quarters > 2 > income Statement > dividends Per Share

-

Quarters > 2 > income Statement > shares Outstanding

101943000

Quarters > 2 > income Statement > income Tax Expense

609000

Quarters > 2 > income Statement > EBITDA

-219315000

Quarters > 2 > income Statement > operating Margin

-

Quarters > 2 > income Statement > total Other Income Expense Net

493000

Quarters > 2 > balance Sheet > cash

98417000

Quarters > 2 > balance Sheet > short Term Investments

224332000

Quarters > 2 > balance Sheet > receivables

-

Quarters > 2 > balance Sheet > inventories

-

Quarters > 2 > balance Sheet > total Current Assets

382757000

Quarters > 2 > balance Sheet > property Plant Equipment

53222000

Quarters > 2 > balance Sheet > total Assets

458946000

Quarters > 2 > balance Sheet > payables

19142000

Quarters > 2 > balance Sheet > short Term Debt

4708000

Quarters > 2 > balance Sheet > long Term Debt

-

Quarters > 2 > balance Sheet > total Liabilities

199451000

Quarters > 2 > balance Sheet > equity

259495000

Quarters > 2 > cash Flow > net Income

-221677000

Quarters > 2 > cash Flow > depreciation

2246000

Quarters > 2 > cash Flow > change In Working Capital

-4365000

Quarters > 2 > cash Flow > cash From Operations

-165124000

Quarters > 2 > cash Flow > capital Expenditures

461000

Quarters > 2 > cash Flow > cash From Investing

164879000

Quarters > 2 > cash Flow > cash From Financing

369000

Quarters > 2 > cash Flow > net Change In Cash

147000

Quarters > 2 > ratios > PE

-2.1745190940035117

Quarters > 2 > ratios > PB

4.529577795333243

Quarters > 2 > ratios > ROE

-85.42630879207692

Quarters > 2 > ratios > ROA

-48.301325210373335

Quarters > 2 > ratios > FCF

-165585000

Quarters > 2 > ratios > Piotroski FScore

1

Quarters > 2 > ratios > fcf Percent

-

Quarters > 2 > health Score

34

Quarters > 3 > quarter

2024-12-31

Quarters > 3 > income Statement > revenue

3836000

Quarters > 3 > income Statement > cost Of Revenue

1918000

Quarters > 3 > income Statement > gross Profit

1918000

Quarters > 3 > income Statement > operating Expenses

189931000

Quarters > 3 > income Statement > operating Income

-189931000

Quarters > 3 > income Statement > interest Expense

-

Quarters > 3 > income Statement > pretax Income

-186795000

Quarters > 3 > income Statement > net Income

-186843000

Quarters > 3 > income Statement > eps

-1.8489238533471872

Quarters > 3 > income Statement > dividends Per Share

-

Quarters > 3 > income Statement > shares Outstanding

101055000

Quarters > 3 > income Statement > income Tax Expense

48000

Quarters > 3 > income Statement > EBITDA

-187470000

Quarters > 3 > income Statement > operating Margin

-4951.2773722627735

Quarters > 3 > income Statement > total Other Income Expense Net

3136000

Quarters > 3 > balance Sheet > cash

99134000

Quarters > 3 > balance Sheet > short Term Investments

386857000

Quarters > 3 > balance Sheet > receivables

2597000

Quarters > 3 > balance Sheet > inventories

-

Quarters > 3 > balance Sheet > total Current Assets

538472000

Quarters > 3 > balance Sheet > property Plant Equipment

53711000

Quarters > 3 > balance Sheet > total Assets

615107000

Quarters > 3 > balance Sheet > payables

18029000

Quarters > 3 > balance Sheet > short Term Debt

3802000

Quarters > 3 > balance Sheet > long Term Debt

-

Quarters > 3 > balance Sheet > total Liabilities

191671000

Quarters > 3 > balance Sheet > equity

423436000

Quarters > 3 > cash Flow > net Income

-186843000

Quarters > 3 > cash Flow > depreciation

2461000

Quarters > 3 > cash Flow > change In Working Capital

-6015000

Quarters > 3 > cash Flow > cash From Operations

-170742000

Quarters > 3 > cash Flow > capital Expenditures

49000

Quarters > 3 > cash Flow > cash From Investing

-87676000

Quarters > 3 > cash Flow > cash From Financing

272853000

Quarters > 3 > cash Flow > net Change In Cash

14523000

Quarters > 3 > ratios > PE

-1.8489238533471872

Quarters > 3 > ratios > PB

2.7516889211120454

Quarters > 3 > ratios > ROE

-44.12544044436467

Quarters > 3 > ratios > ROA

-30.37569073348214

Quarters > 3 > ratios > FCF

-170791000

Quarters > 3 > ratios > Piotroski FScore

1

Quarters > 3 > ratios > fcf Percent

-44.52320125130344

Quarters > 3 > health Score

35

Valuation > metrics > PE

-1.6391148486853069

Valuation > metrics > PB

-71.09833264219114

Valuation > final Score

50

Valuation > verdict

Fair

Profitability > metrics > ROE

1010.7400932400932

Profitability > metrics > ROA

-53.59547610586654

Profitability > final Score

55

Profitability > verdict

Weak

Risk > metrics > Interest Coverage

-153.2868778280543

Risk > final Score

-583

Risk > verdict

High

Liquidity > metrics > Current Ratio

14.068382384906316

Liquidity > metrics > Quick Ratio

14.068382384906316

Liquidity > final Score

100

Liquidity > verdict

Great

Prev Valuations > 0

20

Prev Valuations > 1

34.704222046667574

Prev Valuations > 2

80

Prev Profitabilities > 0

15

Prev Profitabilities > 1

15

Prev Profitabilities > 2

0

Prev Risks > 0

-66

Prev Risks > 1

-458

Prev Risks > 2

-1066

Prev Liquidities > 0

100

Prev Liquidities > 1

100

Prev Liquidities > 2

100

Updated At

2025-12-14T00:16:42.407Z